top of page

A Novel Gene Therapy Vector

Propriety Gene Vectors

  • Based on a triple mutant AAV6.2FF capsid
    • Lower immunogenicity
    • Improved transgene expression
  • Cellexa [adeno-associated virus (AAV6) human ensereptide-Fc fusion protein gene therapy]

  • The ensereptide in Cellexa is the human lactoferrin derived peptide linked to human Fc protein.  This is Cellastra's Anti-Scaring Fusion protein.

  • The ensereptide (PXL01) has been shown to have higher anti-inflammatory, anti-scarring and anti-bacterial properties, than its full molecule i.e., lactoferrin

  • Scarlexa and Fibrexa are different formulations of Cellexa, where Scarlexa is a dermal formulation and Fibrexa is inhaled formulation.

Mechanism of Action

Programmed Gene Vectors
Ensereptide mechanism of action

Expression of Gene Vector in Mice

Days of PXL01 presence in tissue
Gene vector PXL01 expression  in mice of  PXL01  for 77 Days

Product Candidates

Fibrexa for mitigation of respiratory infections

FIBREXA  is a formulation for inhalation by high risk patients e.g. elderly or other patients with risk factors for developing long-term complications with fibrosis after respiratory infections (eg. Influenza, RSV and COVID-19).

Lung, normal vs. pulmary fibrosis

Figure showing normal lung vs. idiopathic (unknown cause) pulmonary fibrosis.

Scarlexa to prevent dermal scarring after burn injuries

Gene therapy for dermal application to prevent scarring after burn injury. Applied topically by spray or ointment suitable for larger body surface area.  

Large burn image of skin

Scarlexa to prevent scarring or adhesions after surgery

For prevention of scarring or adhesions after surgery, Scarlexa is applied before wound closure or injected subcutaneously into the wound area. Shown below is adhesions of the lung (a). Surgery is often used to remove adhesions (b). Treatment with Scarlexa prevents the return of adhesions.

Fibrosis of lung

a

Before and after removal of adhesion in body cavity

b

How Does It Work?

​Administration of the viral gene vector:

  • May Enable continuous production of anti-scarring peptides in the cells of the wound area for many weeks or months.

  • May Help mitigate hyper-immune response (cytokine storm), excessive fibrin formation, secondary infections and excessive scar/fibrosis formation.

​​The peptide disrupts root causes of scarring

Cross-section of skin inflammation
a: Reduced blocking increases fibrinolysis and scar resolution  b  Blocked fibrinolysis promotes scarring
  •  Inflammation promotes severe scarring

a: Reduced blocking increases fibrinolysis and scar resolution

b  Blocked fibrinolysis promotes scarring

Corona virus
  • Infections cause inflammation which increases scar formation

Cellastra Inc., 201 Spear Street , San Francisco, #1100 CA 94105

©2025 by Cellastra Inc. Proudly created with Wix.com

bottom of page